Scherr DS - Search Results

1

Does preoperative symptom classification impact prognosis in patients with clinically localized upper-tract urothelial carcinoma managed by radical nephroureterectomy?

Raman JD, Shariat SF, Karakiewicz PI, Lotan Y, Sagalowsky AI, Roscigno M, Montorsi F, Bolenz C, Weizer AZ, Wheat JC, Ng CK, Scherr DS, Remzi M, Waldert M, Wood CG, Margulis V; Upper-Tract Urothelial Carcinoma Collaborative Group. Raman JD, et al. Among authors: scherr ds. Urol Oncol. 2011 Nov-Dec;29(6):716-23. doi: 10.1016/j.urolonc.2009.11.007. Epub 2010 Jan 6. Urol Oncol. 2011. PMID: 20056458

2

Prostate biopsy techniques and indications: when, where, and how?

Scherr DS, Eastham J, Ohori M, Scardino PT. Scherr DS, et al. Semin Urol Oncol. 2002 Feb;20(1):18-31. doi: 10.1053/suro.2002.30395. Semin Urol Oncol. 2002. PMID: 11828354 Review.

3

Practice patterns among urologic surgeons treating localized renal cell carcinoma in the laparoscopic age: technology versus oncology.

Scherr DS, Ng C, Munver R, Sosa RE, Vaughan ED Jr, Del Pizzo J. Scherr DS, et al. Urology. 2003 Dec;62(6):1007-11. doi: 10.1016/s0090-4295(03)00773-8. Urology. 2003. PMID: 14665345

4

Abnormal selective cytology results predict recurrence of upper-tract transitional-cell carcinoma treated with ureteroscopic laser ablation.

Boorjian S, Ng C, Munver R, Palese MA, Sosa RE, Vaughan ED, Del Pizzo JJ, Scherr DS. Boorjian S, et al. Among authors: scherr ds. J Endourol. 2004 Nov;18(9):912-6. doi: 10.1089/end.2004.18.912. J Endourol. 2004. PMID: 15659932

5

Prostate-specific antigen screening in a high-risk population: lessons from the community and how they relate to large-scale population-based studies.

Shelton JB, Barocas DA, Conway F, Hart K, Nelson K, Richstone L, Gonzalez RR, Raman JD, Scherr DS. Shelton JB, et al. Among authors: scherr ds. Urology. 2005 May;65(5):931-6. doi: 10.1016/j.urology.2004.11.047. Urology. 2005. PMID: 15882726

6

Impact of delay to nephroureterectomy for patients undergoing ureteroscopic biopsy and laser tumor ablation of upper tract transitional cell carcinoma.

Boorjian S, Ng C, Munver R, Palese MA, Vaughan ED Jr, Sosa RE, Del Pizzo JJ, Scherr DS. Boorjian S, et al. Among authors: scherr ds. Urology. 2005 Aug;66(2):283-7. doi: 10.1016/j.urology.2005.02.022. Urology. 2005. PMID: 16098357

7

Bladder cancer after managing upper urinary tract transitional cell carcinoma: predictive factors and pathology.

Raman JD, Ng CK, Boorjian SA, Vaughan ED Jr, Sosa RE, Scherr DS. Raman JD, et al. Among authors: scherr ds. BJU Int. 2005 Nov;96(7):1031-5. doi: 10.1111/j.1464-410X.2005.05804.x. BJU Int. 2005. PMID: 16225523

8

Decreased expression of the human stem cell marker, Rex-1 (zfp-42), in renal cell carcinoma.

Raman JD, Mongan NP, Liu L, Tickoo SK, Nanus DM, Scherr DS, Gudas LJ. Raman JD, et al. Among authors: scherr ds. Carcinogenesis. 2006 Mar;27(3):499-507. doi: 10.1093/carcin/bgi299. Epub 2005 Dec 12. Carcinogenesis. 2006. PMID: 16344273

9

Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder.

Raman JD, Mongan NP, Tickoo SK, Boorjian SA, Scherr DS, Gudas LJ. Raman JD, et al. Among authors: scherr ds. Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8570-6. doi: 10.1158/1078-0432.CCR-05-1047. Clin Cancer Res. 2005. PMID: 16361539

10

Pathologic features of bladder tumors after nephroureterectomy or segmental ureterectomy for upper urinary tract transitional cell carcinoma.

Raman JD, Sosa RE, Vaughan ED Jr, Scherr DS. Raman JD, et al. Among authors: scherr ds. Urology. 2007 Feb;69(2):251-4. doi: 10.1016/j.urology.2006.09.065. Urology. 2007. PMID: 17320658

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

280 results

Search Page

Filters